FXS6837 for the Treatment for IgAN Patients（Longterm Study）

NCT07750665 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgAN

Interventions

DRUG: FXS6837 Capsule

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.